Olympus builds regenerative medicine ops with purchase of Stryker's OP-1 business
This article was originally published in Scrip
Executive Summary
Olympus Corp has set up a new biotech operation in the US based on assets in the bone osteogenic protein-1 (OP-1) field it is acquiring for $60 million from Stryker.